Convalescent Plasma / Royal College of Surgeons in Ireland - LARVOL DELTA

Epidemiology of Neonatal COVID-19 in the United States. (PubMed, Pediatrics) - "Most neonates infected with SARS-CoV-2 were asymptomatic or developed mild illness without need for respiratory support. Some neonates had severe illness requiring treatment for COVID-19 with remdesivir and CCP. Thus, SARS-CoV-2 infection in neonates, though rare, may result in severe disease."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. (PubMed, BMC Infect Dis) - "Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care."

Clinical • Journal • Retrospective data • Review • Critical care • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. (PubMed, Sci Rep) - P=N/A | "There were no significant differences in the primary or secondary outcome measures between CP and standard therapy, although a larger definitive study is needed for confirmation. However, the study did show that CP therapy appears to be safe in hospitalized COVID-19 patients with hypoxia.Clinical trials registration NCT04356534: 22/04/2020."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease

An Overview of Current Knowledge of Deadly CoVs and Their Interface with Innate Immunity. (PubMed, Viruses) - "Despite the rapid application of a range of therapies for SARS-CoV-2, such as convalescent plasma, remdesivir, hydroxychloroquine and type I interferon, no fully effective treatment has been determined. Here, we summarise an up-to-date understanding of epidemiology, immunomodulation and ongoing anti-viral and immunosuppressive treatment strategies. Indeed, understanding the interplay between coronaviruses and the anti-viral immune response is crucial to identifying novel targets for therapeutic intervention, which may even prove invaluable for the control of future emerging coronavirus."

Journal • Review • Acute Respiratory Distress Syndrome • Immune Modulation • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases

Convalescent Plasma Trial in COVID -19 Patients (clinicaltrials.gov) - P=N/A; N=40; Completed; Sponsor: Royal College of Surgeons in Ireland - Medical University of Bahrain; Recruiting ➔ Completed

Clinical • Trial completion • Infectious Disease • Novel Coronavirus Disease • CRP

Convalescent Plasma Trial in COVID -19 Patients (clinicaltrials.gov) - P=N/A; N=40; Recruiting; Sponsor: Royal College of Surgeons in Ireland - Medical University of Bahrain; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • CRP